| 1 |
33915655 | [Changes of immunohistochemical biomarkers before and after neoadjuvant chemotherapy in breast cancer and their prognosis]. | 2021 May 8 |
1 |
| 2 |
32613608 | Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients. | 2020 Oct |
3 |
| 3 |
30659433 | Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. | 2019 Apr |
1 |
| 4 |
30923569 | Breast cancer involvement of the nipple-areola complex and implications for nipple-sparing mastectomies: a retrospective observational study in 137 patients. | 2019 |
3 |
| 5 |
29440915 | Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer. | 2018 |
5 |
| 6 |
29514654 | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. | 2018 Mar 7 |
3 |
| 7 |
28247194 | Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. | 2017 Aug |
2 |
| 8 |
28560596 | Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. | 2017 Sep |
1 |
| 9 |
26338270 | Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. | 2016 Apr |
2 |
| 10 |
26273337 | Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients. | 2015 Jan |
3 |
| 11 |
26345461 | ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. | 2015 Sep 7 |
1 |
| 12 |
26384297 | Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. | 2015 Nov 3 |
2 |
| 13 |
25536590 | Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer. | 2014 Oct-Dec |
2 |
| 14 |
23696593 | Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer. | 2013 Jun |
1 |
| 15 |
24183366 | Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. | 2013 Dec |
3 |
| 16 |
21508407 | Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. | 2011 Apr |
2 |
| 17 |
19730975 | Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. | 2010 Oct |
2 |